Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China flag China · Delayed Price · Currency is CNY
64.39
-2.12 (-3.19%)
Feb 13, 2026, 3:00 PM CST

SHA:688513 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
1,3271,3481,1161,1701,023921.48
Other Revenue
1.841.841.420.630.070.44
1,3291,3501,1171,1711,023921.92
Revenue Growth (YoY)
1.66%20.82%-4.56%14.43%10.96%-2.67%
Cost of Revenue
359.51345.23226.94199.11146.32107.68
Gross Profit
969.441,005890.18971.4876.62814.23
Selling, General & Admin
514.96552.93483.43564.44528.06526.16
Research & Development
257.94262.77237.45229.99199.59153.17
Other Operating Expenses
49.3317.3717.4618.1515.7514.07
Operating Expenses
821.29836.11737.98814741.14695.52
Operating Income
148.15168.42152.2157.4135.47118.72
Interest Expense
-2.6-3.68-3.42-2.61-0.36-0.72
Interest & Investment Income
23.727.3825.6120.6932.8313.26
Currency Exchange Gain (Loss)
0.160.1600.030.02-0.01
Other Non Operating Income (Expenses)
0.020.28-0.1-0.11-0.190.1
EBT Excluding Unusual Items
169.43192.56174.29175.41167.77131.35
Gain (Loss) on Sale of Investments
14.7614.9214.5719.9913.69-
Gain (Loss) on Sale of Assets
-0.09-0.110.030.19-0.1-0.01
Other Unusual Items
81.2545.2252.7666.465.5667.71
Pretax Income
263.31252.59241.64261.99246.92199.05
Income Tax Expense
21.9414.3515.0715.4714.4920.89
Net Income
241.37238.23226.57246.52232.43178.16
Net Income to Common
241.37238.23226.57246.52232.43178.16
Net Income Growth
-3.40%5.15%-8.09%6.06%30.46%64.04%
Shares Outstanding (Basic)
176175177177176147
Shares Outstanding (Diluted)
176175177177176147
Shares Change (YoY)
-0.11%-1.04%0.14%0.37%19.70%11.50%
EPS (Basic)
1.371.361.281.391.321.21
EPS (Diluted)
1.371.361.281.391.321.21
EPS Growth
-3.30%6.25%-8.22%5.68%8.98%47.12%
Free Cash Flow
252.27145.8299.99-187.38-122.59-42.28
Free Cash Flow Per Share
1.430.830.56-1.06-0.70-0.29
Dividend Per Share
0.4300.4300.3950.3810.5310.204
Dividend Growth
8.97%8.97%3.57%-28.19%159.97%-
Gross Margin
72.95%74.42%79.68%82.99%85.70%88.32%
Operating Margin
11.15%12.48%13.62%13.45%13.24%12.88%
Profit Margin
18.16%17.65%20.28%21.06%22.72%19.32%
Free Cash Flow Margin
18.98%10.80%8.95%-16.01%-11.98%-4.59%
EBITDA
235.62249.79225.43215.75168.08151.7
EBITDA Margin
17.73%18.51%20.18%18.43%16.43%16.45%
D&A For EBITDA
87.4881.3773.2358.3532.632.98
EBIT
148.15168.42152.2157.4135.47118.72
EBIT Margin
11.15%12.48%13.62%13.45%13.24%12.88%
Effective Tax Rate
8.33%5.68%6.24%5.90%5.87%10.49%
Revenue as Reported
1,3291,3501,1171,1711,023921.92
Advertising Expenses
---403393.56413.35
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.